Teva Pharmaceutical Industries (TEVA) said Tuesday it priced its $2.3 billion senior notes offering, upsized from the previously announced $2 billion.
The offering consists Teva Pharmaceutical Finance Netherlands II's 1 billion euros ($1.13 billion) aggregate principal amount of 4.125% euro-denominated senior notes due 2031; Teva Pharmaceutical Finance Netherlands III's $500 million aggregate principal amount of 6% USD-denominated senior notes due 2032; and Teva Pharmaceutical Finance Netherlands IV's $700 million aggregate principal amount of 5.75% USD-denominated senior notes due 2030.
Teva said it will use the proceeds to fund cash tender offers for certain notes maturing in 2026, 2027, 2029, and 2031, and to repay outstanding debt.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。